Clinical trial
Beta-Cell Function and Sitagliptin Trial (BEST)
NCT00420511 · Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Other · Completed
Key facts
| NCT number | NCT00420511 |
|---|---|
| Title | Beta-Cell Function and Sitagliptin Trial (BEST) |
| Official title | A Randomized Controlled Pilot Study Assessing the Effect of Sitagliptin on the Preservation of Beta-Cell Function in Patients With Type 2 Diabetes |
| Acronym | BEST |
| Lead sponsor | Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Other |
| Collaborators | Merck Sharp & Dohme LLC Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | Sitagliptin, Placebo, metformin |
| Enrollment | 21 |
| Start date | Jan 1, 2007 |
| Primary completion | Sep 1, 2009 |
| Completion | Sep 1, 2009 |
| First posted | Jan 11, 2007 |
| Last update posted | Jan 2, 2012 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: